For a deeper overview, see our Cagrilintide research guide
Your practitioner will discuss the potential benefits, risks and alternatives with you at your consultation.
Contraception Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives
Skin lightening, contrary to advertised claims, is not permanent
In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Evidence: What does the current research actually support, and how preliminary is it